DE69838298T2 - Kontrolle der immunantworten durch regulierung der aktivität von glykosyltransferasen - Google Patents

Kontrolle der immunantworten durch regulierung der aktivität von glykosyltransferasen Download PDF

Info

Publication number
DE69838298T2
DE69838298T2 DE69838298T DE69838298T DE69838298T2 DE 69838298 T2 DE69838298 T2 DE 69838298T2 DE 69838298 T DE69838298 T DE 69838298T DE 69838298 T DE69838298 T DE 69838298T DE 69838298 T2 DE69838298 T2 DE 69838298T2
Authority
DE
Germany
Prior art keywords
cells
sialyltransferase
st6gal
use according
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838298T
Other languages
German (de)
English (en)
Other versions
DE69838298D1 (de
Inventor
Jamey D. San Diego MARTH
James C. Del Mar PAULSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abaron Biosciences Inc Del Mar
University of California
Abaron Biosciences Inc
University of California Berkeley
University of California, San Diego
Original Assignee
Abaron Biosciences Inc Del Mar
University of California
Abaron Biosciences Inc
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abaron Biosciences Inc Del Mar, University of California, Abaron Biosciences Inc, University of California Berkeley, University of California, San Diego filed Critical Abaron Biosciences Inc Del Mar
Publication of DE69838298D1 publication Critical patent/DE69838298D1/de
Application granted granted Critical
Publication of DE69838298T2 publication Critical patent/DE69838298T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
DE69838298T 1997-05-30 1998-05-29 Kontrolle der immunantworten durch regulierung der aktivität von glykosyltransferasen Expired - Lifetime DE69838298T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4830397P 1997-05-30 1997-05-30
US48303P 1997-05-30
PCT/US1998/011260 WO1998054365A1 (en) 1997-05-30 1998-05-29 Control of immune responses by modulating activity of glycosyltransferases

Publications (2)

Publication Number Publication Date
DE69838298D1 DE69838298D1 (de) 2007-10-04
DE69838298T2 true DE69838298T2 (de) 2008-05-15

Family

ID=21953820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838298T Expired - Lifetime DE69838298T2 (de) 1997-05-30 1998-05-29 Kontrolle der immunantworten durch regulierung der aktivität von glykosyltransferasen

Country Status (7)

Country Link
US (2) US6376475B1 (cg-RX-API-DMAC10.html)
EP (1) EP1017846B1 (cg-RX-API-DMAC10.html)
JP (2) JP4451933B2 (cg-RX-API-DMAC10.html)
AT (1) ATE371041T1 (cg-RX-API-DMAC10.html)
AU (1) AU7717598A (cg-RX-API-DMAC10.html)
DE (1) DE69838298T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998054365A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7834800A (en) * 1999-09-30 2001-04-30 Regents Of The University Of California, The Prevention of atherosclerosis and undesired blood clotting by reducing von willebrand factor
US7192914B1 (en) 1999-09-30 2007-03-20 The Regents Of The University Of California Prevention of atherosclerosis and undesired blood clotting by reducing von Willebrand factor
US20060210558A1 (en) * 2000-10-18 2006-09-21 Robert Sackstein Hematopoietic cell selectin ligand polypeptides and methods of use thereof
ES2338757T3 (es) 2000-10-18 2010-05-12 The Brigham And Women's Hospital, Inc. Polipeptidos ligandos para selectina-e/selectina-l de la celula hematopoyetica y metodos de utilizacion de los mismos.
AU2002327097B2 (en) * 2001-08-16 2007-05-24 Japan As Represented By President Of National Centre Of Neurology And Psychiatry Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
US20060074047A1 (en) * 2004-10-06 2006-04-06 Cross Alan S Method of treating inflammation with inhibitors of sialyl transferases
JP4359779B2 (ja) * 2006-01-23 2009-11-04 ソニー株式会社 音響再生装置および音響再生方法
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
JP6334169B2 (ja) * 2010-12-16 2018-05-30 ビーエーエスエフ アグロ ベー.ブイ. 除草剤耐性の増大した植物
JP2014159374A (ja) * 2011-05-20 2014-09-04 Nippon Nohyaku Co Ltd 作物の枯凋落葉剤組成物
AR091489A1 (es) * 2012-06-19 2015-02-11 Basf Se Plantas que tienen una mayor tolerancia a herbicidas inhibidores de la protoporfirinogeno oxidasa (ppo)
EP2887947B1 (en) 2012-08-23 2019-06-05 Seattle Genetics, Inc. Fucose analogues for the treatment of sickle cell disease
JP2016027002A (ja) * 2012-11-16 2016-02-18 日本農薬株式会社 除草剤組成物
JP6172687B2 (ja) 2013-05-02 2017-08-02 国立研究開発法人産業技術総合研究所 シアリル化糖鎖を認識するモノクローナル抗体
US10285976B2 (en) 2013-08-12 2019-05-14 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone treatment for immune modulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352462A (en) * 1982-06-03 1994-10-04 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5461143A (en) * 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
JPH05247078A (ja) 1992-03-03 1993-09-24 Japan Tobacco Inc 糖化合物、シアル酸含有糖鎖類生合成阻害剤、その製造方法、並びに新規な中間体
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
JPH10504707A (ja) 1994-06-15 1998-05-12 アレクション・ファーマシューティカル・インク 異種移植片の超急性拒否反応を減少させる方法
US20040038923A1 (en) * 2000-10-06 2004-02-26 Marth Jamey D. Blocking inflammation by inhibiting sialylation

Also Published As

Publication number Publication date
US6376475B1 (en) 2002-04-23
WO1998054365A1 (en) 1998-12-03
JP2002528037A (ja) 2002-08-27
EP1017846B1 (en) 2007-08-22
EP1017846A1 (en) 2000-07-12
JP2002528036A (ja) 2002-08-27
US20030013636A1 (en) 2003-01-16
ATE371041T1 (de) 2007-09-15
EP1017846A4 (en) 2004-08-11
DE69838298D1 (de) 2007-10-04
JP4451933B2 (ja) 2010-04-14
AU7717598A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
Wang et al. A novel aminophospholipid transporter exclusively expressed in spermatozoa is required for membrane lipid asymmetry and normal fertilization
Smith et al. Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus
US6331658B1 (en) Genetically engineered mammals for use as organ donors
EP1017846B1 (en) Control of immune responses by modulating activity of glycosyltransferases
DE69534227T2 (de) Stoffe und verfahren zur beherrschung der hyperakuten abstossung von menschlichen transplantaten
KR102652838B1 (ko) Mhc 부류 i 및 부류 ii가 결여된 nsg 마우스
US7166278B2 (en) Modified organs and cells for xenotransplantation
Wang et al. Mice with a homozygous deletion of the Mgat2 gene encoding UDP-N-acetylglucosamine: α-6-D-mannoside β1, 2-N-acetylglucosaminyltransferase II: A model for congenital disorder of glycosylation type IIa
US20040038923A1 (en) Blocking inflammation by inhibiting sialylation
Bessler et al. Paroxysmal nocturnal hemoglobinuria: insights from recent advances in molecular biology
Kuan et al. Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase—a key enzyme in lacto-neolacto ganglioside synthesis
Hennet et al. The remodeling of glycoconjugates in mice
Ikematsu et al. Transgenic mouse lines with ectopic expression of α-1, 3-galactosyltransferase: production and characteristics
JP2002530425A (ja) 炎症を処置する際のコア2GlcNAcトランスフェラーゼインヒビターの使用
US7192914B1 (en) Prevention of atherosclerosis and undesired blood clotting by reducing von Willebrand factor
US7674577B2 (en) Diagnosis of human glycosylation disorders
Ohtsubo Targeted genetic inactivation of N-acetylglucosaminyltransferase-IVa impairs insulin secretion from pancreatic β cells and evokes type 2 diabetes
US7256171B1 (en) Use of core 2 G1cNAc transferase inhibitors in treating inflammation
US7273711B1 (en) Diagnosis of human glycosylation disorders
US20080031821A1 (en) USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION
US20080227689A1 (en) Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1
US20070142319A1 (en) Anxiolytic treatment by inhibition of a polysialyltransferase
WO2004006939A1 (en) Blocking inflammation by inhibiting st3-gal-vi activity
Lu Defective pituitary function and gamete interactions in beta-1, 4-galactosyltransferase null mice
WO2001022921A2 (en) Prevention of atherosclerosis and undesired blood clotting by reducing von willebrand factor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition